European Union - English - EMA (European Medicines Agency)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - nervous system - levodopa/carbidopa/entacapone orion is indicated for the treatment of adult patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (ddc)-inhibitor treatment.

United States - English - NLM (National Library of Medicine)

avpak - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets, usp are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies). entacapone tablets, usp effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end-of-dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54 mg (equivalent: carbidopa, qty 50 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; powdered cellulose; trehalose dihydrate; hyprolose; carmellose sodium; sodium sulfate; magnesium stearate; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg); levodopa, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; trehalose dihydrate; hyprolose; sodium sulfate; powdered cellulose; carmellose sodium; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

stada pharmaceuticals australia pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; hyprolose; trehalose dihydrate; magnesium stearate; carmellose sodium; microcrystalline cellulose; titanium dioxide; iron oxide yellow; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 100 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; hyprolose; trehalose dihydrate; magnesium stearate; carmellose sodium; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - entacapone, quantity: 200 mg; levodopa, quantity: 50 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg) - tablet, film coated - excipient ingredients: sodium sulfate; powdered cellulose; magnesium stearate; carmellose sodium; microcrystalline cellulose; trehalose dihydrate; hyprolose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; lecithin - levodopa/carbidopa/entacapone is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.

United States - English - NLM (National Library of Medicine)

american health packaging - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets, usp are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose “wearing-off” in patients with parkinson’s disease (see clinical pharmacology, clinical studies ). entacapone tablets, usp effectiveness has not been systematically evaluated in patients with parkinson’s disease who do not experience end-of-dose “wearing-off”. entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with parkinson's disease (see clinical pharmacology, clinical studies). entacapone tablets' effectiveness has not been systematically evaluated in patients with parkinson's disease who do not experience end-of-dose "wearing-off". entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.

United States - English - NLM (National Library of Medicine)

wockhardt usa llc. - entacapone (unii: 4975g9nm6t) (entacapone - unii:4975g9nm6t) - entacapone 200 mg - entacapone tablets are indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with parkinson's disease (see clinical pharmacology, clinical studies). entacapone tablets' effectiveness has not been systematically evaluated in patients with parkinson's disease who do not experience end-of-dose "wearing-off". entacapone tablets are contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. entacapone is not a controlled substance. animal studies to evaluate the drug abuse and potential dependence have not been conducted. although clinical studies have not revealed any evidence of the potential for abuse, tolerance or physical dependence, systematic studies in humans designed to evaluate these effects have not been performed.